Capecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Response</td><td class="align_center">Number (%)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Complete response</td><td class="align_center">8 (15.7)</td></tr><tr><td class="align_left">Partial response</td><td class="align_center">17 (33.3)</td></tr><tr><td class="align_left">Stable disease</td><td class="align_center">9 (17.6)</td></tr><tr><td class="align_left">Progressive disease</td><td class="align_center">17 (33.3)</td></tr><tr><td class="align_left">ORR</td><td class="align_center">25 (49)</td></tr><tr><td class="align_left">DCR</td><td class="align_center">34 (66.7)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>Abbreviations: DCR: disease control rate; ORR: objective response rate.<br/></div></td></tr></table>

<div>Best response to capecitabine.</div>

Journal of Oncology

tab2

Table 2

Table 2: Capecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer 